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Summary
Background Psoriasis is associated with risk factors for serious infections, but the
independent relationship between psoriasis and serious infection is as yet
unclear.
Objectives To determine whether people with psoriasis have a higher risk of hospi-
talization due to any infection, respiratory infections, soft-tissue and skin infec-
tions, or a higher risk of death due to infection.
Methods We conducted a cohort study of people (≥ 18 years) with psoriasis using
the UK Clinical Practice Research Datalink (CPRD GOLD) linked to Hospital Epi-
sode Statistics (HES) and Office for National Statistics (ONS) mortality records
between 1 April 2003 and 31 December 2016, and matched with up to six com-
parators on age, sex and general practice. Hospitalization was ascertained from
HES records; death was ascertained from ONS mortality records. Stratified Cox
proportional hazard models were estimated, with stepwise adjustment in differ-
ent models for potential confounders or mediators between psoriasis and serious
infection.
Results There were 69 315 people with psoriasis and 338 620 comparators who
were followed up for a median (interquartile range) of 49 (59) and 51 (63)
years, respectively. People with psoriasis had a higher incidence rate of serious
infection [205 per 1000 person-years, 95% confidence interval (CI) 200–210,
n = 7631] compared with those without psoriasis (161 per 1000 person-years,
95% CI 159–163, n = 30 761). The fully adjusted hazard ratio for the associa-
tion between psoriasis and serious infection was 136 (95% CI 131–140), with
similar results across the other outcomes.
Conclusions Psoriasis is associated with a small increase in the risk of serious infec-
tion. Further research is needed to understand how psoriasis predisposes to a
higher risk of infection.
What is already known about this topic?
• Several studies have shown that people with psoriasis have a higher risk of hospi-
talization due to infection, but these studies are limited by residual confounding
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What does this study add?
• Using a large primary care database linked with secondary care Hospital Episode
Statistics, we found that, after adjusting for potential confounders and mediators,
the hazard ratio for the association between psoriasis and the development of seri-
ous infection was 136 (95% confidence interval 131–140).
• In summary, we show that having psoriasis is independently associated with a
small but increased risk of serious infection.
Psoriasis is a chronic and debilitating disease leading to signifi-
cant morbidity. An important concern of patients with psoria-
sis and healthcare professionals is whether psoriasis is
associated with serious infections, defined as infections that
lead to hospitalization and are therefore associated with signif-
icant morbidity and/or mortality.
A significant contributor to the ill health of patients with
psoriasis is the association with multiple comorbid conditions.
The causal direction of the relationships between psoriasis and
these conditions is complex and incompletely understood, but
associations between psoriasis and potential risk factors such
as obesity, high alcohol intake and smoking have been recog-
nized in multiple observational studies.1–4 However, there is
uncertainty over whether having psoriasis predisposes to a
higher risk of serious infection independent of these other fac-
tors. Studies that have investigated the relationship between
psoriasis and serious infection have been limited thus far by a
lack of adjustment for lifestyle factors5 and potential misclassi-
fication by trying to determine hospital admissions using pri-
mary care electronic health records.6,7
Our aim in this study was to investigate the risk of hospital-
ization and death due to infection in patients with psoriasis in
a large population-based UK cohort of primary care patients
with linked hospital and mortality records.
Methods
Study design and setting
We performed a cohort study using data from the UK Clinical
Practice Research Datalink (CPRD GOLD). The CPRD GOLD is
a primary care database of prospectively collected anonymized
medical records, covering patient information from general
practices in the UK. Clinical events, including diagnoses, are
coded using Read codes.8 We utilized the data from a subset
of general practices from England that were eligible for link-
age to the national Hospital Episode Statistics (HES), Office for
National Statistics (ONS) mortality records and Index of Multi-
ple Deprivation 2010 (IMD) data.9 The IMD is calculated
based on the postcode of the place of residence of the individ-
ual, and is an area-level index of deprivation. In the linked
data, diagnoses are coded using International Classification of
Diseases, 10th revision (ICD-10) codes and procedures are
coded using the Office of Population Censuses and Surveys
Classification of Interventions and Procedures codes.
Study population
Adults (≥ 18 years) with psoriasis who had linked HES, ONS
and IMD data and had been registered with their practice for
at least 1 year prior to the first coded diagnosis of psoriasis in
the study window from the CPRD were eligible for this study.
Incident density sampling was used to identify up to six com-
parators matched by exact age, sex and general practice on
index date to each patient with psoriasis. Comparators had to
have had a consultation with the general practice within 6
months before or after the index date of the people with pso-
riasis to whom they were matched to be included. The study
period was between 1 April 2003 and 31 December 2016. All
individuals were followed up from the index date to the earli-
est date out of the outcome of interest, end of the study per-
iod, last date of data collection from the practice, date on
which the patient transferred out from the practice, or the
date of death (Figure 1).
Exclusion
Individuals with a history of hospitalization due to infection
prior to the index date were identified using the main out-
come codes from the linked HES data and were excluded from
analysis. We also excluded individuals with a diagnosis of
human immunodeficiency virus infection prior to the index
date.
Definition of severe and active psoriasis
Two stratification methods were used to identify people who
had severe psoriasis, and people who had predominantly
active psoriasis. Individuals were defined as having severe pso-
riasis from the timepoint when they received a systemic treat-
ment (acitretin, etretinate, ciclosporin, hydroxycarbamide,
methotrexate and fumaric acid esters), phototherapy or a bio-
logic therapy (etanercept, adalimumab, infliximab, ustek-
inumab, secukinumab and efalizumab) until the end of
follow-up time using data from primary care records; i.e. as a
time-varying covariate.
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Similar to a recent publication about atopic eczema,10
individuals were classified to have active psoriasis at the lat-
est of two CPRD or HES psoriasis records of either diagnoses
or treatment appearing within a period of 1 year. Active
psoriasis was assumed to last for 1 year, and prolonged for
another year if another psoriasis entry was recorded before
the year ended. People with psoriasis were then categorized
into those who had no active psoriasis during follow-up,
those who had active psoriasis for less than 50% of follow-
up, and those who had active psoriasis for at least 50% of
follow-up.
A sensitivity analysis was performed to improve the identifi-
cation of people with severe psoriasis. Using data from the
linked outpatient HES records, we improved the classification
of phototherapy using the linked HES phototherapy records.
We further defined severe psoriasis as people with psoriasis
consulting a dermatologist in secondary care more than twice
in 1 year, with the definition of severe psoriasis starting from
the timepoint of the second consultation.
Identification of outcomes
The primary outcome of hospitalization due to infection and
the secondary outcomes of hospitalization due to respiratory
and skin/soft-tissue infections were identified using linked
data from HES, with any code in any episode. Death due to
infection was identified from the primary cause of death listed
in the ONS mortality records. The list of infections is provided
in Table S1 (see Supporting Information). To test for potential
unmeasured confounding, we included a negative control out-
come, namely hospitalization due to transport accident. This
outcome was chosen as there was little biological plausibility
for this to be associated with psoriasis, and we were able to
control for confounding from alcohol between psoriasis and
transport accidents. This outcome was identified from the
linked HES data. All ICD-10 codes for the outcomes are listed
in Table S1 (see Supporting Information) and are listed via
the Clinical Codes repository11 at https://clinicalcodes.rss.
mhs.man.ac.uk.
Figure 1 Graphical depiction of cohort study design, describing the setting, relevant dates of cohort entry, follow-up, covariate assessment and
exit of the cohort.
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Covariates
We developed a directed acyclic graph to identify covariates that
might be potential confounders, mediators or colliders (Fig-
ure S1; see Supporting Information). We identified two tiers of
covariates to adjust for in the analysis. The first tier included
covariates that are plausible potential confounders. These
included age, IMD status, body mass index (BMI), alcohol
intake and smoking status. Age was mean-centred and modelled
as a cubic term to account for nonlinearity. BMI was determined
using the mibmi command in Stata,12 and the closest BMI to
the index date was taken. BMI readings taken more than 5 years
before or after the index date were classed as missing. Alcohol
intake was established using an existing algorithm13 where the
most recent record prior to or recorded on the index date was
used. Smoking status was also established using an existing
algorithm using information closest to the index date,14 and
separated into current, former and never smokers.
The second tier included covariates that were comorbid
conditions that could be confounders or mediators for the
relationship between infection and psoriasis. These included
other immune-mediated inflammatory diseases (IMID, a com-
posite covariate representing rheumatological conditions,
inflammatory bowel disease and multiple sclerosis), diabetes
and chronic obstructive pulmonary disease (COPD). Diabetes,
IMIDs and COPD were included as time-varying covariates.
Statistical analyses
We estimated incidence rates of the primary and secondary
outcomes for the psoriasis and comparison cohorts. We used
Cox proportional hazards regression, stratified by matched set,
to obtain hazard ratios (HRs) and 95% confidence intervals
(CIs) to investigate the association between psoriasis and the
primary and secondary outcomes. We tested for potential
effect modification for age and sex with psoriasis. If this test
was significant, we explored the impact of effect modification
in separate stratified models, and also included an interaction
term to account for this in the multivariable regression mod-
els. We also tested for the proportionality assumption for the
effect of having psoriasis on serious infection using log–log
plots and comparisons between Kaplan–Meier observed sur-
vival curves and Cox predicted curves.
We performed several models sequentially including the
different aforementioned groups of covariates to estimate the
potential association; and to understand the effect of each
group of covariates between the relationship of the exposure
and the outcome. To investigate the effect of missing data, we
performed multiple imputations of 20 datasets in the primary
analyses, and complete case analysis was performed as a sensi-
tivity analysis. Table 1 shows the other different sensitivity
analyses that were conducted. We also calculated absolute risk
differences for 5 years and 10 years after diagnosis using the
nonparametric baseline survival and the estimated linear pre-
dictor from the Cox model.
This study was approved by the Independent Scientific
Advisory Committee (ISAC) for Medicines and Healthcare
Products Regulatory Agency database research (ISAC approval
18_012R). Analyses were performed using Stata version 15
(StataCorp, College Station, TX, USA). This study is reported
according to the RECORD guidelines.15
Results
A total of 69 315 people with psoriasis and 338 620 compar-
ison individuals were eligible for inclusion in the study
Table 1 Sensitivity analyses
Sensitivity analysis Justification
The primary analysis was repeated in restricted
psoriasis cohorts of mild or severe psoriasis. As this is
a time-varying covariate, follow-up for mild psoriasis
would be censored if the patient developed severe
psoriasis when mild psoriasis cohort was restricted for
To investigate whether the risk of serious infection associated with
psoriasis varies with severity of psoriasis or if it is associated with
systemic therapies for psoriasis
The primary analysis was repeated on an incident
psoriasis cohort
To limit the impact of left-censorship, especially because covariates
measured at entry will precede onset of psoriasis for this subgroup and
therefore will not be on the causal pathway between psoriasis and
infection
The overall cohort was restricted to those having
average mean consultations over one, three and five
per year during follow-up
To investigate the potential impact of detection bias
The secondary outcome was substituted by
hospitalization due to lower respiratory tract
infection, and two analyses performed, one with the
outcome obtained from Read codes and one from
ICD-10 codes
To investigate whether misclassification could be introduced if primary
care health records were used to determine infection, assuming that
hospital ICD-10 codes are the gold-standard way of measuring
hospitalization. Read codes from a recent study on serious infection risk
in patients with psoriasis were used,6 determining the outcomes from
cases which led to hospitalization within 30 days
ICD, International Classification of Diseases.
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(Figure S2; see Supporting Information). At cohort entry, the
median age and interquartile range (IQR) for the psoriasis and
comparison cohorts were 490 (270) and 480 (280),
respectively (Table 2). There was a higher prevalence of obese
individuals in the psoriasis cohort (243%) compared with the
comparison cohort (198%). There was also a higher preva-
lence of heavy drinkers (165%) and current smokers (325%)
in the psoriasis cohort compared with the comparison cohort
(132% and 272%, respectively; Table 2). Similarly, there
was a higher prevalence of all included comorbidities at base-
line in the psoriasis cohort compared with those without pso-
riasis. Within the psoriasis cohort, 2324 individuals (34%)
had severe psoriasis at baseline. Most individuals (829%) in
the psoriasis cohort had active psoriasis over their follow-up
period (Table 2).
Overall, 7631 (110%) of the psoriasis cohort and 30 761
(91%) of the comparison cohort developed an infection
requiring hospitalization within a median (IQR) of 49 (59)
and 51 (63) years of follow-up, respectively. The crude inci-
dence rate of hospitalization due to any infection was 205 per
1000 person-years (95% CI 200–210) in the psoriasis cohort
compared with 161 per 1000 person-years (95% CI 159–
163) in those without psoriasis. Similarly, there were higher
crude incidence rates for hospitalization due to respiratory
infections, soft-tissue and skin infections, and death due to any
infection in the psoriasis cohort compared with the compar-
ison cohort (Table 3). The incidence rate of infection requir-
ing hospitalization was similar between the prevalent and
incident psoriasis subgroups. However, the incidence rate of
infections requiring hospitalization was higher during the
Table 2 Comparison of characteristics at baseline for psoriasis and comparison cohorts
Baseline characteristics Comparison cohort (n = 338 620) Psoriasis cohort (n = 69 315)
Age (years), median (IQR) 490 (270) 480 (280)
Male, n (%) 154 159 (455) 33 522 (484)
Body mass index (kg m2) categories, n (%)
Underweight, < 185 5285 (16) 949 (14)
Normal, 185–249 94 061 (278) 18 136 (262)
Overweight, 250–299 91 810 (271) 19 688 (284)
Obese, ≥ 300 67 100 (198) 16 820 (243)
Missing 80 364 (237) 13 722 (198)
Alcohol intake, n (%)
Nondrinker 29 565 (87) 5552 (80)
Light drinker 47 899 (141) 9291 (134)
Former drinker 26 415 (78) 5700 (82)
Moderate drinker 129 963 (384) 25 736 (371)
Heavy drinker 44 761 (132) 11 471 (165)
Missing 60 017 (177) 11 565 (167)
Smoking status, n (%)
Never smoker 137 263 (405) 22 773 (329)
Ex-smoker 101 915 (301) 23 378 (337)
Current smoker 92 008 (272) 22 506 (325)
Missing 7434 (22) 658 (09)
Index of multiple deprivation score quintile, n (%)
1 (least deprived) 82 762 (244) 16 273 (235)
2 78 559 (232) 15 454 (223)
3 67 463 (199) 13 944 (201)
4 61 620 (182) 13 101 (189)
5 (most deprived) 47 938 (142) 10 485 (151)
Missing 278 (01) 58 (01)
Comorbidities at baseline, n (%)
COPD 6909 (20) 2397 (35)
Diabetes 18 433 (54) 4132 (60)
Immune-mediated inflammatory diseases, n (%)
All 5891 (17) 2935 (42)
Inflammatory bowel disease 628 (02) 807 (12)
Multiple sclerosis 0 (00) 170 (02)
Rheumatological diseases 5284 (16) 1963 (28)
Disease characteristics at baseline, n (%)
Severe psoriasis – 2324 (34)
No active psoriasis – 11 841 (171)
Active psoriasis < 50% F/U – 15 456 (223)
Active psoriasis ≥ 50% F/U – 42 018 (606)
COPD, chronic obstructive pulmonary disease; F/U, follow-up; IQR, interquartile range.
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severe psoriasis exposure time compared with those in the
mild psoriasis exposure time, and higher during the active
psoriasis exposure time compared with people with nonactive
psoriasis exposure time (Table S2; see Supporting Informa-
tion).
The unadjusted HR for hospitalizations due to any infection
was 146 (95% 142–150) (Table 4). There was evidence of
variation of the risk of infection by age (P < 0001, Table S3;
see Supporting Information). The stratified unadjusted HRs for
BMI categories show a higher risk of serious infection in the
underweight category (HR 207, 95% CI 083–515) (data not
shown), while there was an increasing risk of serious infec-
tion with increasing age categories defined by quintiles
(Table S3; see Supporting Information). The log–log plot did
not indicate a violation to the proportionality assumption.
The fully adjusted HR for comorbid conditions and lifestyle
factor covariates was 136 (95% 131–140, Table 4). There
were similar findings across the secondary outcomes, with the
highest adjusted HR found for skin and soft-tissue infections
(HR 156, 95% CI 143–170). The HR for the negative con-
trol outcome was not significantly raised in the unadjusted
analysis (HR 109, 95% 096–124) and the adjusted analysis
(HR 114, 95% CI 100–131, Table 4). The complete case
models yielded similar results with higher effect estimates for
the control outcome (HR 130, 95% CI 109–155, Table S4;
see Supporting Information).
There was a higher unadjusted HR for serious infection in
the incident psoriasis cohort (HR 156, 95% CI 151–161)
compared with the prevalent psoriasis cohort (HR 128, 95%
CI 123–132), but little difference in the effect estimates after
adjustment (Table S5; see Supporting Information). The unad-
justed and adjusted HRs for serious infection were also similar
between mild and severe psoriasis exposure time with the sen-
sitivity analysis including outpatient HES information to
enhance severity definition yielding little difference in the esti-
mated outcomes. There appeared to be a dose–response rela-
tionship with increasing serious infection risk with increased
activity of psoriasis (Table S5; see Supporting Information).
The sensitivity analysis investigating the effect of restricting to
different number of average consultations per year found
attenuated effect estimates for serious infection (Table S6; see
Supporting Information).
When exploring the benefit of using linked HES records to
ascertain infection outcomes rather than primary care records,
we found an overall incidence rate for serious lower respira-
tory tract infections (LRTIs) of 22 (95% CI 21–22) per
1000 person-years using Read codes to ascertain LRTI hospi-
talizations and 32 (95% CI 31–33) using ICD-10 codes to
ascertain LRTI hospitalizations. The use of Read codes also
introduced differential misclassification leading to a change in
Table 3 Event count and incidence rates of primary and secondary
outcomes in the psoriasis and comparison cohorts
Characteristics Comparison cohort Psoriasis cohort
Patients per cohort, n 338 620 69 315
Follow-up (median,
IQR) years
51 (63) 49 (59)
Median survival time
(95% CI), years
162 (160–164) 137 (137–137)
Person-years 1 911 456 372 353
Hospitalization due to any infectiona




161 (159–163) 205 (200–210)
Hospitalization due to respiratory infectionsa




61 (60–62) 74 (71–77)
Hospitalization due to soft-tissue and skin infectionsa




20 (19–21) 31 (29–33)
Death due to any infection




14 (13–14) 16 (15–17)
CI, confidence interval; IQR, interquartile range. aFirst hospital-
ization due to infection event.
Table 4 Hazard ratios (95% confidence intervals) for primary and secondary outcomes comparing the people with psoriasis with the comparison
cohort (multiple imputation analysis)
Analysis Unadjusted Model 1a Model 2b
Hospitalizations due to any infection 146 (142–150) 136 (131–141) 136 (131–140)
Hospitalization due to respiratory infections 144 (138–151) 137 (129–146) 135 (127–144)
Hospitalization due to skin and soft-tissue infections 168 (156–181) 155 (142–169) 156 (143–170)
Death due to infection 130 (118–143) 140 (114–171) 133 (108–163)
Control outcome: hospitalization due to transport accidents 109 (096–124) 114 (100–130) 114 (100–131)
aAdjusted for age (mean-centred and modelled as a cubic term), Index of Multiple Deprivation, body mass index, alcohol intake, smoking
status, interaction term between psoriasis and age; missing data imputed. bCovariates adjusted in Model 1 + diabetes, chronic obstructive pul-
monary disease, other immune-mediated inflammatory diseases; missing data imputed.
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the relative risk with a small overestimate of the effect of pso-
riasis on the risk of serious infection with a HR of 140 (95%
CI 123–159) compared with using ICD-10 codes (HR 133,
95% 121–147, Table S7; see Supporting Information).
Discussion
We found that people with psoriasis had an increased risk of
hospitalization due to any infection. Hospitalizations due to
respiratory infections, soft-tissue and skin infections were also
increased. We also identified that people with psoriasis had a
higher risk of death due to any infection compared with peo-
ple without psoriasis. The elevated risk was attenuated but
persisted after adjustment for potential confounders and medi-
ators. We did not find a dose–response relationship between
severity of psoriasis and serious infection, but we found that
having active psoriasis for over half of the follow-up period
was associated with the highest risk of serious infection.
The use of linked HES data to ascertain the primary and sec-
ondary outcome helps to avoid outcome misclassification and
is a major strength of this study. HES data are used for moni-
toring of secondary care activity and activity-based payment,
and as such are highly robust. Forty-four per cent of all hospi-
talizations recorded in HES, using people with diabetes as an
exemplar,7 were not captured in the CPRD within  30 days.
We found that the use of primary care data alone to ascertain
hospitalization outcome for LRTI would have underestimated
the incidence rate by 31% (Table S7; see Supporting Informa-
tion). The use of outpatient HES data, especially including data
on phototherapy, also helps avoid misclassification of disease
severity. We were able to include lifestyle factors and BMI
from the rich primary care data in the CPRD, enabling us to
adjust for these important potential confounders and/or medi-
ators. The CPRD is representative of the general population of
the UK.16
There is potential for exposure, comorbidity and disease
severity misclassification, as these definitions are not prede-
fined but rather extracted through the use of coding algo-
rithms, and we lack quantitative measures of disease severity.
Specifically, capture of systemic medication use for the treat-
ment of psoriasis is low and likely to introduce misclassifica-
tion. However, the use of validated coding algorithms, for
example to ascertain people with psoriasis17 and the comor-
bidities,12,18 reduces the risk of misclassification. There are
missing data for some of the covariates, and we may not be
able to account for this adequately if the data were not miss-
ing at random. Our analysis focusing on psoriasis activity
across the follow-up period should be interpreted with care as
those with a shorter or longer duration of follow-up might be
more likely to have active disease for the majority of the fol-
low-up and these analyses are not time-updated.
There is also potential for residual confounding and detec-
tion bias. The sensitivity analysis restricting for increasing
average mean consultations throughout follow-up, which may
be a proxy for either unmeasured confounding through multi-
morbidity or an increased propensity for seeking healthcare
consultations, found a persistent but attenuated elevated risk
of serious infection in people with psoriasis. Similarly, we
found an elevated risk of death due to infection in people
with psoriasis, suggesting that detection bias does not fully
explain the association between psoriasis and infection. Con-
trary to the other studies, we did not find a dose–response
relationship between psoriasis severity, modelled as a time-
varying covariate, and infection. As psoriasis severity is defined
by exposure to systemic treatments, it is surprising that the
exposure time with the addition of systemic treatments in
people with psoriasis was not associated with an increased risk
for serious infection, suggesting that there was misclassifica-
tion for this variable.
There are similarities between our findings and two earlier
observational studies that have also investigated the relative risk
of hospitalization due to infection in large population cohorts
of people with and without psoriasis. A Dutch population-
based cohort from the PHARMO Record Linkage System of
25 742 people with psoriasis found an incidence rate of seri-
ous infection of 91 per 1000 person-years in the psoriasis
cohort, and crude and adjusted HRs of 208 (95% CI 196–
222) and 158 (95% CI 148–168), respectively.5 A key limi-
tation of this study was the lack of data on lifestyle factors such
as BMI, smoking and alcohol. A recently published study used
data from The Health Improvement Network (THIN) in the
UK, a similar primary care electronic medical records database
to the CPRD.6 This reported a crude incidence rate of serious
infection of 79 per 1000 person-years in a cohort of 199 700
people with psoriasis. The study found a crude and adjusted
HR of 114 (95% CI 112–116) and 121 (95% CI 118–
123), respectively. An important limitation in this study was
the use of primary care data only to ascertain hospitalization
due to infection, which may explain the lower incidence rates.
In terms of the implications for patients and clinicians,
there is an increased risk of serious infection associated with
having psoriasis. This increased risk is consistent across the
two most common site-specific infections – respiratory and
soft-tissue/skin infections. We also found an increased risk of
death due to infection in people with psoriasis. The absolute
risk difference in probability of serious infection between peo-
ple with psoriasis and the comparison group is low at 077%
(95% CI 069–086%) at 5 years and 312% (95% CI 277–
347%) at 10 years (Table S8; see Supporting Information).
Patients should therefore be counselled that any increased risk
of serious infection independently associated with having pso-
riasis is small.
The mechanism by which psoriasis predisposes to infection
is unclear. Although there are higher levels of antimicrobial
peptides such as b-defensin in plaques of psoriasis, we found
a higher risk of cellulitis and soft-tissue infections in people
with psoriasis. A maladaptive immune response to skin micro-
biota in psoriasis may explain these findings, with people with
psoriasis more likely to be colonized with Staphylococcus aureus
than healthy controls.19 The skew towards an excessive
inflammatory cytokine milieu in psoriasis, in particular
tumour necrosis factor-a and interleukin 17,20 can also be
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associated with the inflammation and tissue damage seen in
bacterial21 and viral infections, and may be the reason for the
higher associated morbidity and severity of infections in our
cohort of people with psoriasis. Excessive levels of pro-inflam-
matory cytokines can lead to dysregulation of the immune
response and induce pathological inflammatory changes asso-
ciated with septic shock.22,23
In conclusion, people with psoriasis have a small but
increased risk of serious infection compared with people with-
out psoriasis. People with psoriasis should not be unduly con-
cerned about the risk of serious infection associated with the
disease, because the absolute risks are small. There was no evi-
dence that psoriasis had a protective effect against skin and
soft-tissue infections. Future research should consider mecha-
nistic work to understand how psoriasis predisposes to a
higher risk of infection.
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